The ticker MANE has moved nearly 500% since its SPAC debut. For those who watch markets the way botanists watch root systems, this is not a number—it is a signal. Veradermics, a company with no approved product, no Phase III data, and a mechanism of action that remains undisclosed, has become the third-largest gainer in the biotech sector this quarter. Absci, an AI-driven protein engineering firm, has doubled. Cosmo Pharmaceuticals, the quiet European, has published late-stage results that the market has chosen to interpret as a green light.
I have spent the last decade watching capital flow into narratives that promise to rewrite the human body the way smart contracts rewrote finance. The pattern is familiar. A market that has been stagnant for thirty years. A patient population measured in the tens of millions. A handful of companies with differentiated technical approaches. And a giant—in this case, Eli Lilly—placing a strategic bet that validates the entire thesis.
But here is what the market is not seeing. The same structural flaws that plague DeFi's liquidity fragmentation are now visible in this emerging therapeutic landscape. And the lessons from one ecosystem may be the only thing that saves the other.
The Context: A Market Frozen in Time
Androgenetic alopecia—pattern baldness—affects approximately 80 million Americans. Fifty million men, thirty million women. Globally, the number exceeds one billion. The last genuinely new mechanism of action approved for this condition was finasteride, in 1997. Before that, minoxidil, in the 1980s. Thirty years of therapeutic silence.
The existing standard of care is a study in compromise. Finasteride, a 5-alpha-reductase inhibitor, works in roughly 60-70% of patients but carries a 2-5% risk of sexual dysfunction—a side effect that drives a 30% discontinuation rate. Minoxidil, a potassium channel opener, achieves only 40% efficacy and requires daily topical application that many patients abandon within months. Neither is approved for women, leaving half the affected population without a pharmacological option.
This is the void that Veradermics, Absci, and Cosmo Pharmaceuticals are racing to fill. Each has chosen a different route. Veradermics is developing an oral small molecule. Absci is engineering an injectable biologic requiring dosing only two to three times over six months. Cosmo is advancing a topical solution with a cleaner systemic safety profile.
Three paths. One destination. And a market that has been waiting thirty years for any of them to arrive.
The Core: Three Architectures, One Fragmentation Problem
Let me be precise about what each company is actually building, because the technical distinctions matter more than the market narrative suggests.
Veradermics' VDPHL01 is an oral therapy that, based on available information, appears to target the androgen pathway—the same biological terrain as finasteride. The innovation, if it exists, lies in molecular design: a new chemical entity that may achieve better efficacy or a cleaner safety profile than the incumbent. This is a Me-better strategy, not a First-in-class one. The company has not disclosed its mechanism of action, which is itself a signal. If they had a novel target—Wnt pathway modulation, JAK inhibition, something beyond the androgen axis—they would be shouting it from every rooftop. Silence is the loudest warning.
Absci's approach is more interesting, not because of the drug itself but because of the platform. The company is an AI-native protein engineering firm. Eli Lilly's $40 million investment is not a bet on a single molecule; it is a bet on the engine that produces molecules. The injectable format, dosed every two to three months, addresses the compliance problem that plagues daily oral therapies. The GLP-1 precedent—semaglutide and tirzepatide generating over $20 billion in annual sales—has normalized the idea of patients self-administering injections for chronic conditions. The infrastructure of acceptance already exists.
Cosmo Pharmaceuticals is the sleeper. A European dermatology specialist with deep experience in topical formulations, the company has published positive late-stage data. It is likely to be first to market, which in this context means a two-to-three-year head start. The topical route avoids systemic exposure, which addresses the safety concerns that drive finasteride discontinuation. But topicals have historically underperformed orals in efficacy, and the transdermal absorption challenge is non-trivial.
Here is where the DeFi parallel becomes unavoidable. In 2021, we saw dozens of Layer-2 solutions launch simultaneously, each claiming to solve Ethereum's scalability problem. The result was not scaling—it was fragmentation. Liquidity that had been concentrated in a single pool was sliced into dozens of thinner, less efficient pools. The same user base. The same transactions. Just spread thinner.
The hair loss market is heading toward the same outcome. Three companies, three mechanisms, three routes of administration, all targeting the same 80 million American patients. If all three succeed, the market will not be three times larger—it will be three times more confusing. Physicians will have to choose between an oral with unknown safety data, an injectable with convenience but higher cost, and a topical with better tolerability but potentially lower efficacy. Patients will face a decision matrix that most are not equipped to navigate.
The Contrarian: The Pragmatism Test
Let me play devil's advocate against my own skepticism. The bull case for this sector is not irrational.
The market is real. The unmet need is genuine. The GLP-1 playbook has demonstrated that consumers will pay out-of-pocket for treatments that improve appearance and confidence, even when those treatments are not covered by insurance. Eli Lilly's market cap has grown by roughly 350% over five years, driven largely by weight-loss drugs that operate in the same consumer-medical gray zone.
But here is the uncomfortable question: what happens when the first clinical data reads out?
None of these companies has disclosed efficacy rates, safety signals, or sample sizes. The phrase "positive late-stage results" from Cosmo is encouraging but unquantified. We do not know the hair count increase. We do not know the responder rate. We do not know how the data compares to finasteride's historical performance. The market is pricing these companies on narrative, not on numbers.
I have audited enough governance tokens to recognize the pattern. A project raises $100 million on the strength of a whitepaper. The community celebrates. The token pumps. Then the code is audited and the vulnerabilities emerge. The same dynamic is playing out here, except the "code" is clinical data and the "audit" is the FDA review process.
There is also the competitive threat that the market is ignoring. Online platforms like Hims & Hers have already commoditized the existing standard of care, offering finasteride and minoxidil through subscription models at prices that undercut traditional channels. These platforms have built the direct-to-consumer infrastructure that new entrants will need to compete with. And in China, domestic players like SanSheng Pharmaceutical and Hengrui are developing their own candidates for a market of 250 million potential patients.
The Takeaway: Proof of Human Intent
I have been thinking about what this moment means for the intersection of biotechnology and blockchain. The convergence is not about tokenizing clinical trials or putting patient data on-chain—those are solutions in search of problems. The real intersection is more fundamental.
Blockchain's deepest value proposition is the ability to verify authenticity in an age of synthetic everything. Proof of Human Intent—the cryptographic verification that a piece of content, a transaction, or a decision originated from a human being with genuine agency—is the natural extension of this principle. The hair loss market, for all its consumer appeal, is ultimately about human identity. The fear of losing one's hair is a fear of losing one's self-presentation, one's youth, one's place in the social hierarchy.
The companies that will win in this market are not necessarily the ones with the best molecules. They are the ones that understand the emotional architecture of their patients. The ones that build trust through transparency rather than hype. The ones that recognize that a treatment for hair loss is not a commodity—it is a restoration of agency.
DeFi breathes; it does not shout. The protocols that survived the bear market were not the loudest ones. They were the ones with sound architecture, honest documentation, and communities that understood the underlying mechanics. The same principle applies here.
Veradermics, Absci, and Cosmo are all building something real. But the market's current enthusiasm is pricing in success before the data exists to justify it. Prune the dead branches, save the tree. The companies that survive will be the ones that can demonstrate, with rigor and transparency, that their molecules actually work.
Geometry remembers what markets forget. The geometry of this market is still being drawn. The question is whether the lines will converge into a coherent picture or fragment into a thousand disconnected points. The answer will come not from the ticker tape, but from the clinical data that has yet to be revealed.
I am watching. I am waiting. And I am reminded that in both biology and code, the most important structures are the ones that hold their shape under pressure.
